Finally, we show that L-asparaginase along with the Bcl-2/Bcl-xL inhibitor ABT263 reduced tumor growth in vivo more efficiently than each compound on its own without induction of significant toxicity, providing a proof of concept that glioblastoma cells are more susceptible to treatments involving L-asparaginase. Here, ASPG is linked to neoplasm.